GlassScriptPhysician profile
Ramzi N Ghosn
NPI 1407943301
$17,260.44
in general payments reported to CMS, 2019-2025
63 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,036 · 2020: $2,663 · 2021: $4,416 · 2022: $2,660 · 2023: $1,583 · 2024: $1,543 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,485.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,650.63 | 2019-2025 | |
| Amgen INC. | $1,331.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,286.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,043.34 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $1,042.21 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $871.93 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $810.19 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $571.41 | 2019-2025 | Rexulti |
| Pfizer INC. | $562.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $560.12 | 2022-2025 | |
| Amarin Pharma, INC. | $516.00 | 2019-2022 | |
| Horizon Therapeutics Plc | $511.17 | 2019-2021 | |
| Esperion Therapeutics, INC. | $451.36 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $424.78 | 2019-2024 | |
| Allergan, INC. | $400.54 | 2019-2021 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $337.06 | 2019-2024 | Qelbree, Qelbree |
| Eisai INC. | $326.48 | 2020-2022 | |
| Lilly USA, LLC | $306.08 | 2020-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $289.90 | 2020-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $276.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.60 | 2019-2023 | Trintellix |
| Grifols USA, LLC | $241.54 | 2019-2024 | Prolastin-C Liquid |
| Biogen, INC. | $236.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $190.51 | 2019-2025 | Belsomra, Steglatro, Januvia |
| Medtronic, INC. | $162.97 | 2025 | Intellis Adaptivestim, Interstim, Inceptiv |
| Neurelis, INC. | $162.22 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.66 | 2020-2025 | Xifaxan |
| Dexcom, INC. | $134.28 | 2023-2025 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $132.63 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.95 | 2025 | Caplyta |
| Indivior INC. | $111.37 | 2024-2025 | Sublocade |
| Inspire Medical Systems, INC. | $102.48 | 2024-2025 | Inspire |
| Vanda Pharmaceuticals INC. | $101.64 | 2025 | Fanapt |
| Ucb, INC. | $96.84 | 2023-2024 | Nayzilam |
| Corcept Therapeutics | $96.79 | 2023-2024 | Korlym |
| Alkermes, INC. | $95.15 | 2021-2025 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $83.74 | 2019-2021 | |
| Daiichi Sankyo INC. | $64.29 | 2019-2021 | |
| Abbott Laboratories | $63.15 | 2023-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $59.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $58.36 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $55.89 | 2020-2021 | |
| Axsome Therapeutics, INC. | $52.11 | 2025 | Symbravo, Auvelity |
| Exact Sciences Corporation | $50.35 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $49.01 | 2023-2024 | Veozah |
| Acclarent, INC | $49.00 | 2019 | |
| Mylan Specialty L.P. | $47.25 | 2021-2022 | |
| Janssen Biotech, INC. | $45.78 | 2019 | |
| Corium, LLC | $43.41 | 2023 | Adlarity |
| Genentech USA, INC. | $36.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $35.75 | 2025 | Voquezna |
| Tris Pharma INC | $35.57 | 2023 | Dyanavel Xr |
| Currax Pharmaceuticals LLC | $27.32 | 2021-2023 | Contrave |
| Braeburn INC. | $25.00 | 2024 | Brixadi |
| Gilead Sciences, INC. | $20.70 | 2019 | |
| Seqirus USA INC | $20.54 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Regeneron Healthcare Solutions, INC. | $18.08 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.86 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.21 | 2019 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Linus Health, INC. | $11.91 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramzi Ghosn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.